Novartis has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), in Phase I/II trials of patients with non-small cell lung cancer (NSCLC). “Preclinical data suggests that combining molecularly targeted agents with immunotherapies such as nivolumab may ...